BioNTech (NASDAQ:BNTX) Sees Unusually-High Trading Volume – Still a Buy?

BioNTech SE Sponsored ADR (NASDAQ:BNTX) shares saw strong trading volume on Friday . 3,089,034 shares were traded during mid-day trading, an increase of 227% from the previous session’s volume of 945,257 shares.The stock last traded at $94.56 and had previously closed at $104.31.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Truist Financial reiterated a “buy” rating and issued a $155.00 target price (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. HC Wainwright reiterated a “buy” rating and issued a $136.00 target price on shares of BioNTech in a report on Monday, September 8th. JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a research report on Thursday, May 22nd. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. Finally, Morgan Stanley raised their price target on shares of BioNTech from $132.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, July 10th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $135.80.

BioNTech Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The company has a market cap of $23.26 billion, a PE ratio of -60.46 and a beta of 1.39. The company’s 50-day simple moving average is $108.79 and its 200 day simple moving average is $103.91.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The firm had revenue of $306.46 million for the quarter, compared to analysts’ expectations of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.BioNTech’s revenue for the quarter was up 102.6% on a year-over-year basis. During the same period last year, the firm posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently modified their holdings of the company. OneDigital Investment Advisors LLC purchased a new stake in shares of BioNTech during the 1st quarter worth $288,000. GAMMA Investing LLC lifted its position in shares of BioNTech by 5,710.8% during the 1st quarter. GAMMA Investing LLC now owns 53,634 shares of the company’s stock worth $4,884,000 after purchasing an additional 52,711 shares during the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of BioNTech during the 4th quarter worth $238,000. Allianz Asset Management GmbH lifted its position in shares of BioNTech by 44.3% during the 1st quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company’s stock worth $10,989,000 after purchasing an additional 37,075 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of BioNTech by 252.5% during the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock worth $49,625,000 after purchasing an additional 390,360 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.